ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

ClinicalTrials.gov ID: NCT01868997

Public ClinicalTrials.gov record NCT01868997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)

Study identification

NCT ID
NCT01868997
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
88 participants

Conditions and interventions

Interventions

  • normal saline Drug
  • teprotumumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2013
Primary completion
Feb 29, 2016
Completion
Feb 21, 2017
Last update posted
Dec 16, 2024

2013 – 2017

United States locations

U.S. sites
11
U.S. states
11
U.S. cities
11
Facility City State ZIP Site status
Jules Stein Eye Institute at UCLA Los Angeles California 90095
University of Denver Aurora Colorado 80045
Emory University Department of Ophthalmology Atlanta Georgia 30322
University of Iowa Hospitals and Clinics, Department of Ophthalmology Iowa City Iowa 52242
Kellogg Eye Center at University of Michigan Ann Arbor Michigan 48105
Washington University Department of Ophthalmology St Louis Missouri 63110
University of Nebraska Medical Center Department of Ophthalmology Omaha Nebraska 68198
Casey Eye Institute at Oregon Health and Science University Portland Oregon 97239
Hamilton Eye Institute at University of Tennessee Memphis Tennessee 38163
Eye Wellness Center Houston Texas 77005
Medical College of Wisconsin, The Eye Institute Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01868997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2024 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01868997 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →